TOVX (Theriva Biologics) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Theriva Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.61 Mil. Theriva Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.13 Mil. Theriva Biologics's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Theriva Biologics Debt-to-Revenue Historical Data

The historical data trend for Theriva Biologics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Debt-to-Revenue Chart

Theriva Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Theriva Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Theriva Biologics's Debt-to-Revenue

For the Biotechnology subindustry, Theriva Biologics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theriva Biologics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Debt-to-Revenue falls into.

Theriva Biologics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Theriva Biologics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.55	+	1.604)	/	N/A
	=	N/A

Theriva Biologics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.606	+	1.133)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Theriva Biologics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Theriva Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Executives

Steven A Shallcross	director, officer: CEO and CFO	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro	officer: Chief Operating Officer	9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan	director
Scott Tarriff	director	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman	officer: CHIEF MEDICAL OFFICER	9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp	10 percent owner	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne	officer: CHIEF FINANCIAL OFFICER	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks	director	C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr	director, officer: CEO & President	C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome	officer: Chief Scientific Officer	3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman	director
Wayne George Holman	10 percent owner	430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022